I. McFarlane

Learn More
To resolve conflicting reports about the occurrence of antibodies against hepatitis C virus (HCV) in patients with autoimmune chronic active hepatitis (AI-CAH), sera from UK and Italian patients were tested with the original anti-HCV assay (Ortho) and a novel anti-HCV assay (UBI) based entirely on synthetic HCV peptides. 28 (60%) of 47 Italian patients with(More)
The value of serum autoantibodies against the liver-specific membrane lipoprotein (LSP) complex in predicting the outcome of treatment withdrawal was assessed in 22 patients with autoimmune chronic active hepatitis who had been maintained in remission on azathioprine and/or prednisolone. At the start of treatment withdrawal 8 patients had anti-LSP(More)
An enzyme immunoassay (Ortho-HCV ELISA) for antibodies against the hepatitis C virus (HCV) was used to test 143 serum samples from 53 patients with autoimmune chronic active hepatitis (AI-CAH). Optical density (OD) values in the assay correlated closely with serum globulin (r = 0.8846, p much less than 0.0005) and IgG (r = 0.6281, p less than 0.0005)(More)
By means of an indirect T-lymphocyte migration inhibitory factor assay, T-cell sensitisation to the asialoglycoprotein receptor, a liver-specific protein on the surface of hepatocytes, was found in patients with autoimmune chronic active hepatitis (CAH) but not in healthy relatives or spouses. Cellular immunity to a liver-derived lipoprotein complex (LSP)(More)
The sensitisation of helper T cells of patients with autoimmune chronic active hepatitis to a liver-cell membrane-expressed asialoglycoprotein receptor protein is shown to be associated with a defect of T cells that specifically induce suppressor lymphocytes. These lymphocytes are found in an activated state in the peripheral blood of healthy people and may(More)
  • 1